Regulation and localization of endogenous human tristetraprolin

Arthritis Research and Therapy

Volumn 5, Issue 4, 2003, Pages

  Fairhurst, Anna Marie ^a   Connolly, John E ^b   Hintz, Katharine A ^b   Goulding, Nicolas J ^a   Rassias, Athos J ^b   Yeager, Mark P ^b   Rigby, William ^b   Wallace, Paul K ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

endotoxic shock; inflammation; lipopolysaccharide; tristetraprolin

Indexed keywords

DNA BINDING PROTEIN; IMMEDIATE EARLY PROTEIN; LIPOPOLYSACCHARIDE; TRISTETRAPROLIN; TUMOR NECROSIS FACTOR ALPHA; ZFP36 PROTEIN, HUMAN;

ANTIBODY SPECIFICITY; ARTICLE; BIOSYNTHESIS; CELL LINE; CHEMISTRY; CYTOPLASM; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; KINETICS; LEUKOCYTE; METABOLISM; PHYSIOLOGY;

ANTIBODY SPECIFICITY; CELL LINE; CYTOPLASM; DNA-BINDING PROTEINS; FLOW CYTOMETRY; HUMANS; IMMEDIATE-EARLY PROTEINS; KINETICS; LEUKOCYTES; LIPOPOLYSACCHARIDES; TRISTETRAPROLIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1642322476     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar778     Document Type: Article

References (50)

1. Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T: The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med. 1989, 169: 333-338. 10.1084/jem.169.1.333. DOI: 10.1084/jem.169.1.333
2. Tracey KJ, Beutler B, Lowry SF, Merryweather J, Wolpe S, Milsark IW, Hariri RJ, Fahey TJ, Zentella A, Albert JD: Shock and tissue injury induced by recombinant human cachectin. Science. 1986, 234: 470-474. DOI: 10.1126/science.3764421
3. Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J: Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1988, 31: 784-788. DOI: 10.1002/art.1780310614
4. Miesel R, Hartung R, Kroeger H: Priming of NADPH oxidase by tumor necrosis factor alpha in patients with inflammatory and autoimmune rheumatic diseases. Inflammation. 1996, 20: 427-438. 10.1007/BF01486744. DOI: 10.1007/BF01486744
5. Badolato R, Oppenheim JJ: Role of cytokines, acute-phase proteins, and chemokines in the progression of rheumatoid arthritis. Semin Arthritis Rheum. 1996, 26: 526-538. 10.1016/S0049-0172(96)80041-2. DOI: 10.1016/S0049-0172(96)80041-2
6. Brennan FM, Maini RN, Feldmann M: TNF alpha – a pivotal role in rheumatoid arthritis?. Br J Rheumatol. 1992, 31: 293-298. DOI: 10.1093/rheumatology/31.5.293
7. Keating GM, Perry CM: Infliximab: an updated review of its use in Crohn's disease and rheumatoid arthritis. BioDrugs. 2002, 16: 111-148. DOI: 10.2165/00063030-200216020-00005
8. O'Quinn RP, Miller JL: The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: a report of 2 cases. Arch Dermatol. 2002, 138: 644-648. 10.1001/archderm.138.5.644. DOI: 10.1001/archderm.138.5.644
9. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997, 337: 141-147. 10.1056/NEJM199707173370301. DOI: 10.1056/NEJM199707173370301
10. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993, 36: 1681-1690. DOI: 10.1002/art.1780361206
11. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, Cerami A, Wolff SM, Wilmore DW: Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med. 1988, 318: 1481-1486. DOI: 10.1056/NEJM198806093182301
12. Martich GD, Danner RL, Ceska M, Suffredini AF: Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxin: the effect of antiinflammatory agents. J Exp Med. 1991, 173: 1021-1024. 10.1084/jem.173.4.1021. DOI: 10.1084/jem.173.4.1021
13. Eichacker PQ, Hoffman WD, Farese A, Banks SM, Kuo GC, MacVittie TJ, Natanson C: TNF but not IL-1 in dogs causes lethal lung injury and multiple organ dysfunction similar to human sepsis. J Appl Physiol. 1991, 71: 1979-1989.
14. Tracey KJ, Lowry SF, Fahey TJ, Albert JD, Fong Y, Hesse D, Beutler B, Manogue KR, Calvano S, Wei H: Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet. 1987, 164: 415-422.
15. DuBois RN, McLane MW, Ryder K, Lau LF, Nathans D: A growth factor-inducible nuclear protein with a novel cysteine/histidine repetitive sequence. J Biol Chem. 1990, 265: 19185-19191.
16. Varnum BC, Lim RW, Sukhatme VP, Herschman HR: Nucleotide sequence of a cDNA encoding TIS11, a message induced in Swiss 3T3 cells by the tumor promoter tetradecanoyl phorbol acetate. Oncogene. 1989, 4: 119-120.
17. Varnum BC, Ma QF, Chi TH, Fletcher B, Herschman HR: The TIS11 primary response gene is a member of a gene family that encodes proteins with a highly conserved sequence containing an unusual Cys-His repeat. Mol Cell Biol. 1991, 11: 1754-1758. DOI: 10.1128/MCB.11.3.1754
18. Heximer SP, Forsdyke DR: A human putative lymphocyte G0/G1 switch gene homologous to a rodent gene encoding a zinc-binding potential transcription factor. DNA Cell Biol. 1993, 12: 73-88. DOI: 10.1089/dna.1993.12.73
19. Lai WS, Kennington EA, Blackshear PJ: Interactions of CCCH zinc finger proteins with mRNA: non-binding tristetraprolin mutants exert an inhibitory effect on degradation of AU-rich element-containing mRNAs. J Biol Chem. 2002, 277: 9606-9613. 10.1074/jbc.M110395200. DOI: 10.1074/jbc.M110395200
20. Johnson BA, Blackwell TK: Multiple tristetraprolin sequence domains required to induce apoptosis and modulate responses to TNFalpha through distinct pathways. Oncogene. 2002, 21: 4237-4246. 10.1038/sj.onc.1205526. DOI: 10.1038/sj.onc.1205526
21. Murata T, Yoshino Y, Morita N, Kaneda N: Identification of nuclear import and export signals within the structure of the zinc finger protein TIS11. Biochem Biophys Res Commun. 2002, 293: 1242-1247. 10.1016/S0006-291X(02)00363-7. DOI: 10.1016/S0006-291X(02)00363-7
22. Phillips RS, Ramos SB, Blackshear PJ: Members of the tristetraprolin family of tandem CCCH zinc finger proteins exhibit CRM1-dependent nucleocytoplasmic shuttling. J Biol Chem. 2002, 277: 11606-11613. 10.1074/jbc.M111457200. DOI: 10.1074/jbc.M111457200
23. Carballo E, Lai WS, Blackshear PJ: Feedback inhibition of macrophage tumor necrosis factor-alpha production by tristetraprolin. Science. 1998, 281: 1001-1005. 10.1126/science.281.5379.1001. DOI: 10.1126/science.281.5379.1001
24. Brooks SA, Connolly JE, Diegel RJ, Fava RA, Rigby WF: Analysis of the function, expression, and subcellular distribution of human tristetraprolin. Arthritis Rheum. 2002, 46: 1362-1370. 10.1002/art.10235. DOI: 10.1002/art.10235
25. Taylor GA, Thompson MJ, Lai WS, Blackshear PJ: Mitogens stimulate the rapid nuclear to cytosolic translocation of tristetraprolin, a potential zinc-finger transcription factor. Mol Endocrinol. 1996, 10: 140-146. 10.1210/me.10.2.140.
26. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G: Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. Embo J. 1991, 10: 4025-4031.
27. Carballo E, Blackshear PJ: Roles of tumor necrosis factor-alpha receptor subtypes in the pathogenesis of the tristetraprolin-deficiency syndrome. Blood. 2001, 98: 2389-2395. 10.1182/blood.V98.8.2389. DOI: 10.1182/blood.V98.8.2389
28. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G: Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity. 1999, 10: 387-398. 10.1016/S1074-7613(00)80038-2. DOI: 10.1016/S1074-7613(00)80038-2
29. Stoecklin G, Ming XF, Looser R, Moroni C: Somatic mRNA turnover mutants implicate tristetraprolin in the interleukin-3 mRNA degradation pathway. Mol Cell Biol. 2000, 20: 3753-3763. 10.1128/MCB.20.11.3753-3763.2000. DOI: 10.1128/MCB.20.11.3753-3763.2000
30. Zhu W, Brauchle MA, Di Padova F, Gram H, New L, Ono K, Downey JS, Han J: Gene suppression by tristetraprolin and release by the p38 pathway. Am J Physiol Lung Cell Mol Physiol. 2001, 281: L499-508.
31. Guyre PM, Graziano RF, Vance BA, Morganelli PM, Fanger MW: Monoclonal antibodies that bind to distinct epitopes on Fc gamma RI are able to trigger receptor function. J Immunol. 1989, 143: 1650-1655.
32. Suffredini AF, Fantuzzi G, Badolato R, Oppenheim JJ, O'Grady NP: New insights into the biology of the acute phase response. J Clin Immunol. 1999, 19: 203-214. 10.1023/A:1020563913045. DOI: 10.1023/A:1020563913045
33. Beutler B, Poltorak A: Sepsis and evolution of the innate immune response. Crit Care Med. 2001, 29 (suppl 7): S2-6. 10.1097/00003246-200107001-00002. DOI: 10.1097/00003246-200107001-00002
34. Elin RJ, Wolff SM, McAdam KP, Chedid L, Audibert F, Bernard C, Oberling F: Properties of reference Escherichia coli endotoxin and its phthalylated derivative in humans. J Infect Dis. 1981, 144: 329-336. DOI: 10.1093/infdis/144.4.329
35. Jilma B, Blann A, Pernerstorfer T, Stohlawetz P, Eichler HG, Vondrovec B, Amiral J, Richter V, Wagner OF: Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirin. Am J Respir Crit Care Med. 1999, 159: 857-863. DOI: 10.1164/ajrccm.159.3.9805087
36. Suffredini AF, Reda D, Banks SM, Tropea M, Agosti JM, Miller R: Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol. 1995, 155: 5038-5045.
37. Hintz KA, Rassias AJ, Wardwell K, Moss ML, Morganelli PM, Pioli PA, Givan AL, Wallace PK, Yeager MP, Guyre PM: Endotoxin induces rapid metalloproteinase-mediated shedding followed by upregulation of the monocyte hemoglobin scavenger receptor CD163. J Leukoc Biol. 2002, 72: 711-717.
38. Carballo E, Gilkeson GS, Blackshear PJ: Bone marrow transplantation reproduces the tristetraprolin-deficiency syndrome in recombination activating gene-2 (-/-) mice. Evidence that monocyte/macrophage progenitors may be responsible for TNFalpha overproduction. J Clin Invest. 1997, 100: 986-995. DOI: 10.1172/JCI119649
39. Maini RN, Taylor PC: Anti-cytokine therapy for rheumatoid arthritis. Annu Rev Med. 2000, 51: 207-229. 10.1146/annurev.med.51.1.207. DOI: 10.1146/annurev.med.51.1.207
40. Oliver JC, Bland LA, Oettinger CW, Arduino MJ, McAllister SK, Aguero SM, Favero MS: Cytokine kinetics in an in vitro whole blood model following an endotoxin challenge. Lymphokine Cytokine Res. 1993, 12: 115-120.
41. Heinzelmann M, Mercer-Jones MA, Gardner SA, Wilson MA, Polk HC: Bacterial cell wall products increase monocyte HLA-DR and ICAM-1 without affecting lymphocyte CD18 expression. Cell Immunol. 1997, 176: 127-134. 10.1006/cimm.1997.1089. DOI: 10.1006/cimm.1997.1089
42. Medzhitov R, Janeway CA: Innate immunity: impact on the adaptive immune response. Curr Opin Immunol. 1997, 9: 4-9. 10.1016/S0952-7915(97)80152-5. DOI: 10.1016/S0952-7915(97)80152-5
43. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, Kimoto M: MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med. 1999, 189: 1777-1782. 10.1084/jem.189.11.1777. DOI: 10.1084/jem.189.11.1777
44. Wolff SM, Rubenstein M, Mullholland JH, Alling DW: Comparison of hematologic and febrile response to endotoxin in man. Blood. 1965, 26: 190-201.
45. Tracey KJ, Cerami A: Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med. 1994, 45: 491-503. 10.1146/annurev.med.45.1.491. DOI: 10.1146/annurev.med.45.1.491
46. Creasey AA, Stevens P, Kenney J, Allison AC, Warren K, Catlett R, Hinshaw L, Taylor FB: Endotoxin and cytokine profile in plasma of baboons challenged with lethal and sublethal Escherichia coli. Circ Shock. 1991, 33: 84-91.
47. Redl H, Schlag G, Bahrami S, Schade U, Ceska M, Stutz P: Plasma neutrophil activating peptide-1/interleukin-8 and neutrophil elastase in a primate bacteremia model. J Infect Dis. 1991, 164: 383-388. DOI: 10.1093/infdis/164.2.383
48. Beutler B: Regulation of cachectin biosynthesis occurs at multiple levels. Prog Clin Biol Res. 1990, 349: 229-240.
49. Kovacs EJ, Radzioch D, Young HA, Varesio L: Differential inhibition of IL-1 and TNF-alpha mRNA expression by agents which block second messenger pathways in murine macrophages. J Immunol. 1988, 141: 3101-3105.
50. Vassalli P: The pathophysiology of tumor necrosis factors. Annu Rev Immunol. 1992, 10: 411-452. 10.1146/annurev.immunol.10.1.411. DOI: 10.1146/annurev.iy.10.040192.002211